secwatch / observer
8-K filed December 8, 2023, 6:59 PM ET ticker TNXP CIK 0001430306
debt confidence high sentiment neutral materiality 0.65

Tonix Pharmaceuticals Holding Corp. (TNXP): debt financing — Tonix Pharmaceuticals enters $11M term loan with JGB entities; reviews Phase 2 migraine data

Tonix Pharmaceuticals Holding Corp.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Tonix Pharmaceuticals Holding Corp. incurred term loan of $11.0 million with JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd. at greater of (i) the Prime Rate plus 3.5% and (ii) 12% maturing 36-month.

Instrument
term loan
Principal
$11.0 million
Counterparty
JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd.
Rate
greater of (i) the Prime Rate plus 3.5% and (ii) 12%
Maturity
36-month
Event
incurrence
Exact text from the filing
as administrative agent and collateral agent for the Lenders (in such capacity, “ JGB Agent ”) for a 36-month term loan (the “ Term Loan ”) in the aggregate principal amount of $11.0 million. Interest Rate All outstanding amounts under the Term Loan bear interest at a fluctuating per annum interest rate (the “ Applicable Rate ”) equal to the greater of (i) the Prime
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. entered into Loan and Guaranty Agreement with JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd., and JGB Collateral LLC valued at aggregate principal amount of $11.0 million (effective 2023-12-08).

Action
entry
Agreement
credit facility
Counterparty
JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd., and JGB Collateral LLC
Value
aggregate principal amount of $11.0 million
Effective
2023-12-08
Exact text from the filing
On December 8, 2023, Tonix Pharmaceuticals Holding Corp. (the “ Company ”) entered into a Loan and Guaranty Agreement (the “ Loan Agreement ”) by and among the Company, Krele LLC, a wholly-owned subsidiary of Tonix Pharmaceuticals, Inc. (“ Tonix ”), a wholly-owned subsidiary of the Company (“ Krele ”), Jenner Institute, LLC, a wholly-owned subsidiary of Tonix (“ Jenner ”), Tonix R&D Center, a wholly-owned subsidiary of Tonix (“ Tonix R&D ”, and together with the Company, Krele and Jenner, the “ Loan Parties ”), JGB Capital, LP, JGB Partners, LP, JGB (Cayman) Cornish Rock Ltd., and any other lender from time to time party hereto (collectively, the “ Lenders ”), and JGB Collateral LLC, as administrative agent and collateral agent for the Lenders (in such capacity, “ JGB Agent ”) for a 36-month term loan (the “ Term Loan ”) in the aggregate principal amount of $11.0 million.
View on SEC.gov

101 debt financings filed in the last 30 days. Browse all debt financings →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR
accession 0001999371-23-000907
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.